Navigation Links
Doctors Debate Drugs vs. Surgery for Angina
Date:9/14/2007

Data re-analysis supports angioplasty, but not everyone agrees

FRIDAY, Sept. 14 (HealthDay News) -- Controversy still swirls around how doctors can best treat patients with the chest pain called stable angina, with some physicians favoring the use of drugs while others vote for surgery.

The results of a major trial, called the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE), seemed to indicate that drug therapy was preferable to angioplasty, since only drug therapy reduced patients' risk of heart attack and death. Those findings were published in March.

But now, researchers taking a fresh look at the data say the opposite may true. They find that angioplasty is usually the best first line of defense against angina.

Will that settle the issue? It's doubtful, experts say.

"There is a lot of debate on both sides of the issue," said Dr. George A. Diamond, a professor of medicine at the University of California, Los Angeles, and co-author of an accompanying journal editorial.

There's a large group of people who believe that these people need to be treated to remove their symptoms completely, and the best way to do that is with interventional procedures such as angioplasty and stenting, Diamond said.

"However, there is another group of individuals who feel the problem can be handled medically," Diamond said.

In the new review of the COURAGE data, Dr. Dean J. Kereiakes, from Christ Hospital Heart and Vascular Center/The Lindner Research Center in Cincinnati, and colleagues come down on the side of angioplasty as first-line treatment for patients with stable angina.

The study authors noted that COURAGE showed significantly better reduction in angina and a reduction for the need for repeat angioplasty or other invasive procedures compared to drug interventions. In addition, patients treated initially with angioplasty had no increased rates of heart attack or death compared with patients treated with drugs alone.

In the second place, the trial confirmed earlier studies that indicated that not doing angioplasty to open all the patient's narrowed coronary arteries was linked to a poorer outcome and the need for more invasive procedures.

Third, despite intensive medical therapy for stable coronary disease patients -- which Kereiakes sees as unrealistic -- "severe or progressive symptoms led to a surprisingly high rate (32 percent) of 'crossover' to revascularization [surgery] in patients initially assigned to medical therapy alone," they noted in their paper in the Oct. 16 issue of the Journal of the American College of Cardiology, released Friday.

Fourth, Kereiakes' team believes that the clinical benefits of drug therapy plus angioplasty give patients, particularly those with disease in more than one vessel, the biggest benefit in terms of reducing chest pain.

Still, a case-by-case approach may be best, the research team said.

"The choice of therapy (s) for each individual patient must be made based on coronary anatomic suitability and in the context of the patient's lifestyle, functional capacity, level of symptom limitation, and their ability (physically, emotionally, and financially) to take the prescribed treatment," Kereiakes' group noted. "If PCI (angioplasty) revascularization is performed, this procedure should be done using the most complete and effective tools and always in addition to (rather than in place of) medical therapies that reduce [cholesterol] plaque progression," they concluded.

Despite these findings, Diamond said that the COURAGE trial showed that drug therapy was as effective as drug therapy plus angioplasty for patients with stable angina. "Angioplasty provided no additional benefit over optimal medical care," he said. "That gores the ox of those who believe strongly in angioplasty."

Diamond's own stance? He believes angioplasty is the correct initial treatment for patients who have suffered a heart attack but not for patients with chronic stable angina.

"Patients with mild angina should be tried on medical therapy alone," he said. "The evidence has shown that there is a reasonable level of expectancy that that will relieve the symptoms. In addition, it has proven benefit in lowering the risk of heart attack and death, which has not been shown for angioplasty."

Which treatment any patient may get is dependent on the doctor he or she sees, Diamond added. "Truth be told, aside from the emotional belief that opening the vessel gives a better-looking X-ray, the studies don't bear that out," he said. "If you go to a physician who believes in these procedures and does them himself, you are much more likely to get a procedure rather than medical therapy."

Financial incentives also encourage that, Diamond said.

"We get paid a lot more for doing procedures than we do for giving sage advice and simply writing a few prescriptions," he said.

Despite the data, Diamond expects the debate to continue so long as treatment guidelines are ambiguous and don't reflect the latest evidence for the best medical care. "We need to realign the current practice guidelines to be consistent with the evidence," he said.

Patients with angina should have an angiogram before any treatment decisions are made, Kereiakes said. "You have to individually assess every patient to determine their ability emotionally and financially to take the prescribed treatment," he said.

Kereiakes is concerned that patients on drug treatment alone do not comply with their regimen. It doesn't happen in the real world, he added.

Medication and angioplasty are complementary therapies, Kereiakes said. "Most patients with stable angina can't be managed by drugs alone," he said. "But treatment must be individualized."

More information

For more about angina, visit the American Heart Association.



SOURCES: Dean J. Kereiakes, M.D., Christ Hospital Heart and Vascular Center/The Lindner Research Center, Cincinnati; George A. Diamond, M.D., professor, medicine, University of California, Los Angeles; Oct. 16, 2007, Journal of the American College of Cardiology


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Doctors needed urgently in Gujarat
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. Two doctors suspended for wrong brain surgery
5. Doctors at risk- the ugly side of the noble profession
6. Lure of the home turf brings back NRI doctors
7. Thakur warns doctors
8. Negligent doctors asked to cough up 3 lakhs for death of patient
9. Doctors advice early anemia tests
10. Emphasis to ban Drugs ads by Doctors
11. Doctors In UK Have Reservations About NHS Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 ... alone responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To ... 1512, which proposes a tax on prescription opioids to fund drug rehabilitation and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... products to the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin ... knowledgeable ASL friendly staff from Harris Communications and to try out the newest assistive ...
(Date:3/25/2017)... Square, PA (PRWEB) , ... March 25, 2017 , ... ... priority as a public relations partner. , All through the year, Garden Media ... and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, ... material, and hazardous and non-hazardous materials announced today the acquisition of privately owned ... will add four additional processing facilities and a vast array of additional technologies, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of ... their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an ... manufacturing and focuses both on contract manufacturers and cell therapy ... emerge as viable alternatives to conventional treatment options. ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 According ... Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market ... million by 2022, growing at a CAGR of 3.6% during the forecast period. ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
Breaking Medicine Technology: